Medical treatment for primary sclerosing cholangitis: Risk versus benefit
Open Access
- 1 October 2000
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 32 (4) , 871-872
- https://doi.org/10.1002/hep.510320429
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Time Course of Histological Progression in Primary Sclerosing CholangitisAmerican Journal of Gastroenterology, 1999
- Primary sclerosing cholangitisHepatology, 1999
- Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosisGastroenterology, 1997
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study periodJournal of Hepatology, 1994
- Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis: A Placebo–Controlled TrialHepatology, 1992
- Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot studyHepatology, 1991
- Patients with asymptomatic primary sclerosing cholangitis frequently have progressive diseaseGastroenterology, 1990
- A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone lossHepatology, 1989
- AZATHIOPRINE IN PRIMARY SCLEROSING CHOLANGITISThe Lancet, 1971